Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction of New Onset Non-M3 Acute Myelid Leukemia

Next Previous
Trial Profile

Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction of New Onset Non-M3 Acute Myelid Leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Cytarabine; Fludarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms V-FIRST

Most Recent Events

  • 12 Dec 2023 Preliminary results assessing early time-points (TPs) MRD analysis with the aim of identify the most informative TPs for MRD assessment and prognostic correlations, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
  • 12 Dec 2023 Results assessing safety and efficacy of venetoclax (VEN) in combination with FLAI (fludarabine, cytarabine, and idarubicin as a first-line treatment for newly diagnosed adult patients with ELN 2017 intermediate- or high-risk AML) were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
  • 15 Jun 2023 Results evaluating the actual advantage of the addition of venetoclax to chemotherapy by comparing AML1718 , AML1310 and real world data, presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top